[Present status and future prospects for gene therapy in Parkinson's disease].
D000818:Animals; D001142:Aromatic-L-Amino-Acid Decarboxylases / Q000235:genetics; D003342:Corpus Striatum / Q000378:metabolism; D000229:Dependovirus; D004298:Dopamine / Q000096:biosynthesis; D006136:GTP Cyclohydrolase / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D005822:Genetic Vectors; D051100:Glial Cell Line-Derived Neurotrophic Factor; D005968:Glutamate Decarboxylase / Q000235:genetics; D006801:Humans; D009414:Nerve Growth Factors / Q000235:genetics; D010300:Parkinson Disease / Q000628:therapy*; D013787:Thalamic Nuclei; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics
C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D014446:Tyrosine 3-Monooxygenase; D006136:GTP Cyclohydrolase; D005968:Glutamate Decarboxylase; D001142:Aromatic-L-Amino-Acid Decarboxylases; D004298:Dopamine